Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Translational Development Acquisition (TDAC) Shares Outstanding (Weighted Average) (2023 - 2026)

Translational Development Acquisition's Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $17.2 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 270.37% to $17.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.2 million, a 270.37% increase, with the full-year FY2025 number at $15.7 million, changed 0.0% from a year prior.
  • Shares Outstanding (Weighted Average) came in at $17.2 million for Q1 2026, up from $15.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $17.2 million in Q3 2025, with the low at $4.0 million in Q4 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $9.7 million across 4 years, with a median of $4.7 million in 2025.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 325.93% in 2025, while the deepest fall reached 0.0% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $4.0 million in 2023, then surged by 287.65% to $15.7 million in 2024, then changed by 0.0% to $15.7 million in 2025, then grew by 9.87% to $17.2 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TDAC at $17.2 million in Q1 2026, $15.7 million in Q4 2025, and $17.2 million in Q3 2025.